Clinical Trial Update: Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating gossypol acetate added to FOLFIRI and bevacizumab in metastatic colorectal cancer patients who are TP53-mutant and LRPPRC-positive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Gossypol acetate (gossypol acetate)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)

Snippet

Sponsor: Guiying Wang | Conditions: Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment | Phase 2 | Status: NOT_YET_RECRUITING